Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | FADS1 | O60427 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053211 | 0.84 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL595037 | 0.84 | CA1 (0.46) | CA1CA2HTR7NPC1TP53 | |
| SCHEMBL596553 | 0.82 | CA12 (0.37) | CA1CA2HTR7SMN1; SMN2CA12 | |
| SCHEMBL500064 | 0.82 | CA1 (0.49) | CA1CA2HTR7RAB9AFADS1 | |
| SCHEMBL596056 | 0.82 | CA1 (0.39) | CA1CA2RAB9ACA12CA9 | |
| SCHEMBL596495 | 0.81 | CA1 (0.47) | CA1CA2TSHRCA12CA9 | |
| SCHEMBL500078 | 0.81 | CA1 (0.53) | CA1CA2CA12CA9PDE4A | |
| SCHEMBL10053280 | 0.81 | CA1 (0.43) | CA1CA2HTR7NPC1TSHR | |
| SCHEMBL14001035 | 0.81 | CA1 (0.43) | CA1CA2CA12CA9 | |
| SCHEMBL500341 | 0.81 | CA1 (0.43) | CA1CA2HTR7SMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066787-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9572823-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9566290-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566289-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9549938-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9353133-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-7465836-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2007146965-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | ANACOR PHARMACEUTICALS INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007131072-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1638578-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005013892-A9 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2005013892-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885HTR7 3129/4885 |
| US-20170066787-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885HTR7 3129/4885 |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885HTR7 3129/4885 |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885HTR7 3129/4885 |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | BPGM, HMBS, PPIP5K2 | CA1 3204/4885CA2 1752/4885HTR7 3849/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885HTR7 3129/4885 |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | GAA, BTD, MANBA | CA1 838/4885CA2 535/4885HTR7 4403/4885 |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885HTR7 3129/4885 |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | BTD, GAA, GBA3 | CA1 897/4885CA2 491/4885HTR7 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.